During the week of June 15, 2026, FDA issued 25 warning letters to telehealth companies over alleged false or misleading promotional claims about compounded GLP-1 productsclaims the agency views as violating the Federal Food, Drug, and Cosmetic Acts (FDCA) misbranding provisions, including Sections 502(a) and 502(n)
Many users say familiar meals suddenly taste flat, overly sweet, metallic or simply less enjoyable
Oxidant/antioxidant status in premenstrual syndrome
Self-assembled -cyclodextrin as nanocarriers for enhanced ocular drug bioavailability
The committee reviewed BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon and Emideltide (also known as delta sleep-inducing peptide, or DSIP) to determine whether they should be eligible for compounding by 503A pharmacies